Your Ads Privacy ChoicesIMDb Transforming businesses through deep sector expertise and capabilities Accelerating seed-to-scale growth in partnership with visionary leaders Structuring bespoke solutions across asset types Enabling growth through innovative fund strategies and investment solutions across the capital structure Building the next generation of real assets Independent company plans significant investment in innovation both internal product development and external licensing and acquisitions today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (“Tanabe Pharma” “MTPC” or “the Company”) in a carve-out transaction from Mitsubishi Chemical Group Corporation  The investment is being led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team and values the business at approximately 510 billion JPY (3.3 billion USD) Tanabe Pharma is headquartered in Doshomachi the birthplace of Japan’s pharmaceutical industry  Through the discovery and development of innovative drugs that address unmet medical needs MTPC focuses on several priority therapeutic areas  MTPC employs over 5,000 people globally Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through business development commercialization and strategic acquisitions “Tanabe Pharma has been delivering innovative medicines to Japanese patients for centuries and we are proud to partner with MTPC and support its next phase of growth and evolution,” said Masa Suekane Industrials and Financial Services at Bain Capital Private Equity the Company will benefit from the full support of Bain Capital’s global resources and our healthcare team’s extensive experience driving value creation across the healthcare value chain  We look forward to a collaborative partnership with MTPC and helping build a best-in-class Japanese pharma platform.” “We believe there are promising signs for growth and untapped opportunities in Japan’s life sciences industry as government and regulators have launched several initiatives to accelerate the development and approval of innovative medicines in the Japanese market,” said Ricky Sun  “This is an exciting opportunity to leverage our team’s clinical insights and company creation support to build out a scale platform focused on long-term fundamental drug development in areas of significant unmet need to ultimately bring transformative medicines to patients in Japan and globally.” Bain Capital’s global Healthcare platform has deep experience supporting the growth and innovation of global pharmaceutical companies including Aiolos Bio (now part of GSK) The firm is also a leading investor and partner to businesses across Japan with more than 70 investment professionals who have made over 37 investments since establishing its Tokyo office in 2006 The transaction is expected to close in the third quarter of 2025 and is subject to customary closing conditions regulatory clearance and shareholder approvals Mitsubishi UFJ Morgan Stanley Securities and BofA Securities are serving as financial advisors Hamada & Matsumoto and Ropes & Gray are serving as legal advisors to Bain Capital About Mitsubishi Tanabe Pharma CorporationMitsubishi Tanabe Pharma Corporation (MTPC) the pharma arm of Mitsubishi Chemical Group (MCG) is one of the oldest pharmaceutical companies in the world  MTPC sets the MISSION of “Creating hope for all facing illness” MTPC is working on the disease areas of central nervous system MTPC is focusing on “precision medicine” to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety MTPC is working to develop “around the pill solutions” to address specific patient concerns based on therapeutic medicine Bain Capital is one of the world’s leading private investment firms We are committed to creating lasting impact for our investors we lead with conviction and a culture of collaboration advantages that enable us to innovate investment approaches Our global platform invests across five focus areas: Private Equity we bring deep sector expertise and wide-ranging capabilities and approximately $185 billion in assets under management Follow @BainCapital on LinkedIn and X (Twitter).  The Bain Capital square symbol is a trademark of Bain Capital Log in to access your account information. If you have any questions regarding your account, please contact ir@baincapital.com 2025 /PRNewswire/ -- GV20 Therapeutics (GV20) a clinical-stage AI-powered biotherapeutics company has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) which are specifically directed against novel tumor antigen targets discovered through GV20's proprietary STEAD AI platform to generate potentially first-in-class antibody-drug conjugates "This agreement underlines the strength of GV20's STEAD platform in discovering novel tumor targets and human-derived antibodies." said Ying Gong leveraging their deep expertise in linker-payload technology and therapeutics development to advance innovative antibody-drug conjugate (ADC) therapies against these novel targets." GV20 will receive an upfront payment and is eligible for milestone payments MTPC will receive an exclusive right to negotiate a license to these antibodies during the collaboration term GV20-0251 demonstrates safety and promising monotherapy efficacy GV20-0251 advanced from target discovery to IND in three years marking a paradigm shift in AI-driven antibody drug discovery To learn more about GV20, please visit https://gv20tx.com/ and follow the company on LinkedIn Business ContactYing Gong, Ph.D., CBO[email protected] a clinical-stage AI-based next generation biotherapeutics company today announced presentation of clinical results from its Phase .. a clinical-stage AI and genomics-based next generation biotherapeutics company announced today that Dr Health Care & Hospitals Medical Pharmaceuticals Pharmaceuticals Biotechnology Do not sell or share my personal information: under pressure from Japanese authorities to raise corporate and shareholder value.Bain and other foreign funds have ramped up acquisitions helping propel inbound M&A in Japan to the top of the leaderboard in Asia in 2024 for the first time since 1999.($1 = 151.8400 yen)Reporting by Anton Bridge and Kane Wu; Editing by Edwina Gibbs Our Standards: The Thomson Reuters Trust Principles., opens new tab , opens new tab Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts. , opens new tabScreen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. © 2025 Reuters. All rights reserved “What will it take?” This is the mindset Hayden Tanabe ’18 has used throughout his life and career to help him achieve levels of success he never thought possible A natural-born leader with a genuine desire to help others Hayden has amassed an impressive list of accolades in his young adult life He is currently in his second year at Harvard Business School where he’s earning his MBA while serving as student body co-president Hayden was class president in high school and student body president at LMU so he’s got some experience under his belt Hayden hit the ground running in his first year at HBS as a section president for nearly 100 students The feedback he gathered informed his priorities as president Hayden spent his summer building a diverse executive team and developed a roadmap for building campus engagement and accessibility separate from Harvard Business School,” said Hayden This role mixes my love for student government with running a business.” Hayden admits he’s having the best time of his life right now but none of it would be possible without the relationships he made and the experience he had at LMU “LMU positioned me very well for success at HBS.” Hayden chose LMU because he didn’t want to venture too far from home and wanted to get involved on campus immediately He made a splash during his four years at LMU as president of the Residence Hall Association senior vice president of the Delta Sigma Pi business fraternity and member of the MAGIS service organization “I have so many great memories of my time at LMU but serving as ASLMU president my senior year was the highlight of my experience,” said Hayden “There were a lot of tough decisions to be made and it helped me grow as a leader and gave me more conviction in the decisions I’ve made as HBS president.” After graduating from LMU with a degree in management Hayden worked in consulting at EY for five years while continuing to serve his alma mater as the inaugural chair of the LMU Brand Ambassadors Program “Consulting teaches you a lot about different industries; it makes you industry agnostic.” and changing coasts was at the top of his list “I always wanted to go back to school to get my MBA and I yearned for a totally new experience I also really missed the educational environment and being involved in a close-knit community.” Hayden immediately made his mark at Harvard Business School he organized a trip to Croatia for his cohort “It’s been interesting to be in this environment surrounded by so many successful people,” said Hayden “LMU made me think more critically through a Jesuit lens…men and women for others bringing everyone together for…the Jesuit principles I was taught carry with me in my current role.” Hayden is often asked about his plans after Harvard he’s 100% focused on maximizing his experiences and not thinking too far into the future While he doesn’t intend to go back into consulting he thinks everyone should have a big company experience A smaller organization where he can have more autonomy is more appealing to him now “I was never entrepreneurial prior to HBS and now I’m more open to that path,” he says “I don’t know what my future holds or where my journey will take me but I feel more confident being a leader in any space and that’s a good place to be.” See All Campus News Stay up to date on LMU news via email alerts and RSS feeds. Copyright © 2025 Loyola Marymount University Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi Chemical Group Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion dollar deal that brings a portfolio of products marketed globally along with a drug pipeline spanning several key therapeutic areas is the pharmaceutical division of Mitsubishi Chemical Group which traces its origins to a Japanese business started in 1638 will split off from its corporate parent to join Bain The deal values Tanabe Pharma at 510 billion Japanese yen (about $3.3 billion) Mitsubishi Chemical Group said the pharma unit requires large-scale investment to strengthen its R&D capacity and growth which is not feasible under the current ownership “We carefully explored the best owners for Mitsubishi Tanabe Pharma to achieve future growth and we have reached a conclusion that promoting a growth strategy under Bain Capital which has extensive investment experiences in healthcare is the best option,” the conglomerate said Tanabe Pharma currently focuses on immunology and inflammation; vaccines; central nervous system disorders; and diabetes and metabolic disease The unit’s top-selling product is the amyotrophic lateral sclerosis drug Radicava which accounted for 79.2 billion yen (about $523 million) in revenue for the fiscal year ended March 31 Its portfolio also includes the Eli Lilly diabetes drug Mounjaro which it sells in Japan under an agreement with the U.S Tanabe Pharma employs more than 5,000 people globally Bain said the Japanese company will continue to develop innovative drugs internally while also seeking new opportunities for growth through business development including licensing deals and strategic acquisitions In Friday’s acquisition announcement said the investment firm believes there are promising signs for growth and untapped opportunities in Japan’s life sciences industry following government and regulatory initiatives to accelerate the development and approval of innovative medicines in the Japanese market “This is an exciting opportunity to leverage our team’s clinical insights and company creation support to build out a scale platform focused on long-term fundamental drug development in areas of significant unmet need to ultimately bring transformative medicines to patients in Japan and globally,” Sun said which still needs regulatory and shareholder approvals is expected to close in the third quarter of this year The layout of your phlebotomy station can significantly impact efficiency A well-thought-out setup ensures that every tool is within reach minimizing unnecessary movement and reducing patient wait times Finding the best analytics tools for health care revenue management can revolutionize operational processes Compare the leading software options to discover helpful team resources Discover what tools are essential for efficient safe surgical extractions in today’s health care landscape This website is using a security service to protect itself from online attacks The action you just performed triggered the security solution There are several actions that could trigger this block including submitting a certain word or phrase You can email the site owner to let them know you were blocked Please include what you were doing when this page came up and the Cloudflare Ray ID found at the bottom of this page Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry US private equity firm Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit Mitsubishi Tanabe Pharma in a deal valued at approximately Y510bn ($3.3bn) The transaction follows a sale process initiated by Mitsubishi Chemical Group in September 2024 the parent company said that continuous additional investments are essential for enhancing R&D capabilities and achieving further growth It added that Bain’s expertise in healthcare investment was a key reason for its selection offering Mitsubishi Tanabe “multifaceted support from a new partner deeply knowledgeable in the pharmaceuticals business” In December 2024, sources told Reuters that private equity firm Blackstone was also interested in a deal for Mitsubishi Tanabe along with Bain valuing the company at between $3bn and $3.5bn Bain life sciences partner Ricky Sun states that Japan’s regulatory environment is evolving with government initiatives aimed at accelerating drug development and approval: “This is an exciting opportunity to leverage our team’s clinical insights and company creation support to build out a scale platform focused on long-term fundamental drug development in areas of significant unmet need to ultimately bring transformative medicines to patients in Japan and globally.” Synaffix will manufacture ADC-related components while Mitsubishi will oversee the research Financial terms for this agreement were not disclosed Don’t let policy changes catch you off guard Stay proactive with real-time data and expert analysis Other deals include one with Moderna for mRNA vaccines and Eli Lilly Japan for the distribution and marketing of its GIP/GLP-1 receptor agonist blockbuster Mounjaro (tirzepatide) Give your business an edge with our leading industry insights View all newsletters from across the GlobalData Media network Please enable JS and disable any ad blocker iStock, Natalya Kosarevich Bain Capital on Friday dropped $3.3 billion to acquire Mitsubishi Tanabe Pharma Corporation in a carve-out deal giving the investment firm access to the Japanese life sciences space Tanabe will function independently of its previous parent Mitsubishi Chemical Group Corporation and will continue to work on its priority areas diabetes and metabolic diseases and central nervous system conditions Tanabe has around 5,000 employees globally though it is not clear yet how the acquisition will affect them Bain and Tanabe expect to close the acquisition agreement in the third quarter of 2025 necessary regulatory clearances and other customary conditions The buyout is an “exciting opportunity” for the capital manager Bain partner Ricky Sun said in a statement noting that there are “promising signs for growth” in Japan amid “initiatives” from the government and regulatory bodies to “accelerate the development and approval of innovative medicines in the Japanese market.” In April 2024, the Japanese government announced that it would lower the hurdles for international pharmaceutical companies seeking drug approvals in Japan. According to reporting from The Japan News the move was meant to address Japan’s “drug loss” problem where the latest and most effective medicines approved in other countries fail to enter the Japanese market due to its complex approval pathways The proposed guideline changes include a conditional approval program—similar to the FDA’s accelerated pathway—and a special approval process for substitute substances that can be used in case of supply problems Bain closed its fourth fund in September 2024, bringing in around $3 billion to back life science companies developing “transformative medicines and life sciences tools that have the potential to improve the lives of patients with unmet medical needs.” Since its founding in 2016 - Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43 with the potential to address the underlying pathology of <97% of ALS patients - Mitsubishi Tanabe Pharma Corporation obtains an option for a global license to develop and commercialize the novel TDP-43 small molecule condensate modulator - Deal valued at up to $480 million- Dewpoint to receive an upfront and additional development and commercial milestone payments 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc. the leading biotechnology company that develops therapeutics by targeting biomolecular condensates announced today that it has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) to advance Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS) Dewpoint will receive an upfront payment and will be eligible for milestone payments based on specified near-term research and development objectives with a total nominal deal value of up to $480M MTPC will have an exclusive option to license the program and assume responsibility for global clinical development and commercialization Dewpoint will also receive tiered royalties on net sales "We are delighted to collaborate with MTPC in advancing our condensate-modulating approach to address the critical unmet need in the treatment of ALS," said Ameet Nathwani "This partnership underscores the transformative potential of our small molecule condensate modulator which aims to tackle the underlying pathology of ALS and related neurodegenerative diseases via a novel mechanism of action Our c-mod was discovered and developed through Dewpoint's pioneering condensate-targeted platform as the developer of the only FDA-approved therapy for sporadic ALS combined with their global clinical capability and expansive patient network we are poised to accelerate the clinical development of this innovative program and bring hope to patients facing this devastating disease." By leveraging its unique expertise in condensate biology Dewpoint has discovered a small molecule that addresses the mislocalization of the TAR DNA-binding protein 43 (TDP-43) a critical splicing factor implicated in several neurodegenerative diseases and a key pathological feature present in over 97% of ALS patients TDP-43 abnormally accumulates in membrane-less cytoplasmic structures leading to neuronal dysfunction in ALS patients Dewpoint identified a c-mod capable of mitigating these pathological TDP-43 condensates by selectively departitioning TDP-43 and restoring its correct localization into the nucleus while preserving the normal cellular stress response By correcting this disease-driving condensate dysfunction (condensatopathy) the treatment restores TDP-43's normal splicing activity and improves multiple clinically relevant ALS biomarkers in animal models Ameet Nathwani added: “The success we’ve had so far with this c-mod in reversing ALS-associated pathology suggests that this compound may find future applications in other indications which share the TDP-43 condensatopathy.” “ALS remains a critical area of unmet medical needs and MTPC is committed to addressing it as the leading company in ALS therapeutics,” said Masao Nawano “There are limited treatment options for ALS patients where no known underlying genetic cause has been established We are excited to join forces with Dewpoint to advance this promising small molecule c-mod that takes advantage of their unique expertise and cutting-edge technologies in condensate biology we have the potential to deliver meaningful innovations to patients and families affected by this devastating condition This research collaboration and option agreement strategically represents MTPC’s mission: ‘Creating hope for all facing illness.’ Generating new unique compounds to address unmet medical needs and provide clinical benefits are key values of MTPC.“ served as the exclusive financial advisor to Dewpoint Therapeutics About Mitsubishi Tanabe Pharma Corporation +44-7813-346395media@dewpointx.com Head of Investor Relations & External InnovationDewpoint Therapeuticsmfenn@dewpointx.com Presentations will highlight findings from studies evaluating investigational ND0612 in Parkinson's disease and RADICAVA® (edaravone) formulations in ALS 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America (MTPA) announced 11 presentations will be shared at the American Academy of Neurology (AAN) 2025 Annual Meeting The presentations will discuss two posters in Parkinson's disease (PD) and nine in amyotrophic lateral sclerosis (ALS) "We are honored to join the scientific community at this year's AAN meeting where we will discuss key insights from our clinical and real-world studies across PD and ALS," said Gustavo A underscore our dedication to advancing impactful research and deepening our understanding of these progressive neurodegenerative diseases." PD data to be presented at the meeting include: Investigational ND0612:Presentations will highlight findings from the pivotal Phase 3 BouNDless trial (NCT04006210) including an oral presentation detailing the impact of 24-hour treatment with ND0612 on PD motor state transitions throughout the day as well as an analysis of quality of life outcomes in people with PD experiencing motor fluctuations ALS data to be presented at the meeting include: RADICAVA ORS Studies:A presentation will share final results from the MT-1186-A03 extension study which evaluated the safety and tolerability of RADICAVA ORS® (edaravone) over 96 weeks in ALS patients who had previously participated in MT-1186-A01 findings from the MT-1186-A04 extension study will be presented assessing the continued efficacy and safety of RADICAVA ORS over an additional 48 weeks comparing investigational daily dosing with the U.S Food and Drug Administration (FDA)-approved on/off regimen an analysis will examine the impact of RADICAVA ORS on survival and function in ALS patients leveraging data from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database and propensity score matching to compare RADICAVA ORS-treated patients with participants from studies MT-1186-A01 through A04.  Real-World Data:Multiple posters highlighting real-world data will be presented including two studies evaluating at-home telespirometry in ALS One examines changes in erect and supine slow vital capacity based on non-invasive ventilation (NIV) status while the other assesses point-of-care quality classifications for slow and forced vital capacity measurements an analysis of real-world data will examine trends in ALS treatment utilization in the U.S highlighting shifts in prescribing patterns adoption of FDA-approved therapies and the decreasing proportion of untreated patients Other presentations include an analysis of referral patterns and healthcare utilization among people with ALS enrolled in the OPTUM claims database a secondary analysis describing demographics and healthcare resource utilization across specialty vs and the application of a clinical algorithm to electronic medical records to reduce the delay in time to diagnosis and treatment for patients with ALS About RADICAVA ORS® (edaravone)The U.S Food and Drug Administration (FDA) approved RADICAVA ORS® (edaravone) on May 12 for the treatment of amyotrophic lateral sclerosis (ALS) the FDA granted RADICAVA ORS Orphan Drug Exclusivity based on its major contribution to patient care by providing an oral suspension route of administration that avoids the burdens of IV administration RADICAVA ORS is taken daily for 14 consecutive days followed by a 14-day drug-free period for the initial treatment cycle RADICAVA ORS is taken for 10 days within a 14-day period followed by a 14-day drug-free period Each 105 mg (5mL) dose of RADICAVA ORS should be taken in the morning after overnight fasting Patients should not eat or drink (except water) within one hour after taking RADICAVA ORS.1 Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and commercialized in the U.S The MTPC group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period edaravone was approved as RADICUT® for the treatment of ALS in Japan and South Korea Marketing authorizations were subsequently granted in Canada (October 2018) Malaysia (December 2021) and Brazil (February 2024) Marketing authorization for RADICAVA® Oral Suspension was granted in Canada (November 2022) and Switzerland (May 2023) and RADICUT® Oral Suspension 2.1% was granted regulatory approval in Japan in December 2022 along with the previously available IV RADICAVA® (edaravone) have been used to treat over 16,000 people with ALS and have been prescribed by over 2,400 HCPs.2-4 INDICATIONRADICAVA ORS® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS) Hypersensitivity ReactionsRADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product and erythema multiforme) and cases of anaphylaxis (urticaria Patients should be monitored carefully for hypersensitivity reactions Sulfite Allergic ReactionsRADICAVA ORS contain sodium bisulfite a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people Adverse ReactionsThe most common adverse reactions (≥10%) reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%) fatigue was also observed in 7.6% of patients receiving RADICAVA ORS To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch About ND0612 ND0612 is an investigational drug-device combination therapy – a 24-hours/day continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with Parkinson's disease (PD). Development of investigational ND0612 is being led by NeuroDerm Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC).  Media inquiries:[email protected]  1 RADICAVA and RADICAVA ORS Prescribing Information (MTPA) today announced that three poster presentations on investigational ND0612 in Parkinson's disease (PD).. (MTPA) today announced the publication of new preclinical research in Free Radical Biology and Medicine,.. Reporting by Kane Wu in Hong Kong; additional reporting by Chang-ran Kim Mariko Katsumura and Satoshi Sugiyama in Tokyo; Editing by Sumeet Chatterjee By: Charlie Sternberg Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group Corporation The investment values the business at approximately $3.3 billion Through the discovery and development of innovative drugs that address unmet medical needs MTPC will continue to build on its legacy of medical innovation while developing new opportunities for growth through business development the Company will benefit from the full support of Bain Capital’s global resources and our healthcare team’s extensive experience driving value creation across the healthcare value chain.  We look forward to a collaborative partnership with MTPC and helping build a best-in-class Japanese pharma platform.” Don’t miss Contract Pharma’s frequently updated Mergers and Acquisitions Roundup Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced except with the prior written permission of Rodman Media The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff a brief rundown of news involving Mitsubishi Tanabe Pharma and Bausch + Lomb Viracta Therapeutics and X4 Pharmaceuticals that you might have missed Investment firm Bain Capital agreed on Friday to acquire Mitsubishi Tanabe Pharma in a deal that values the nearly 350-year-old pharmaceutical arm of Japan’s Mitsubishi Chemical Group at about $3.3 billion The deal will see the firm separated from its corporate parent where it will continue developing vaccines as well as drugs for neurological cardiometabolic and immunological conditions that there are “promising signs for growth and untapped opportunities in Japan’s life sciences industry,” citing moves by the government and regulators to speed drug development Mitsubishi Tanabe Pharma is headquartered in Osaka and employs more than 5,000 people globally Bausch + Lomb will remain a subsidiary of Bausch Health after sale talks failed to yield an acceptable deal, according to Thursday's announcement. Last year, the company, which sells eye drugs, drops and contact lenses, said it intended to explore a potential sale in an effort to separate itself from its corporate parent it revealed that that process led to an indication of interest from a private equity firm said Bausch + Lomb didn’t receive an offer that reflected its “long-term value.” Bausch Health will keep its 88% stake for the time being but “full separation remains the goal,” Bausch + Lomb said X4 Pharmaceuticals will let go of about 30% of its workforce, or 43 employees, in a bid to focus resources around its top drug program, the company said Thursday the company will pause early drug research Austria and streamline spending to support development and commercialization of mavorixafor which is approved as Xolremdi for the rare disease WHIM syndrome and in late-stage testing in chronic neutropenia X4 also intends to grow its sales and marketing team The moves are expected to reduce annual spending by $30 million to $35 million and extend X4’s ability to operate into 2026 Get the free daily newsletter read by industry experts Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade Just two acquisitions in the first quarter a notable decrease from the six seen during the same period last year Subscribe to the BioPharma Dive free daily newsletter The free newsletter covering the top industry headlines Japan’s Mitsubishi Chemical Group (TYO: 4188) has resolved at a meeting of the board of directors held today which engages in the manufacturing and sales of pharmaceutical products a special purpose company indirectly owned by Bain Capital for around 510 billion yen ($3.36 billion) this would be the largest-ever private equity deal in Japan’s healthcare sector Bain is buying the Tanabe business in the hope that it can tap into its own connections to other global pharmaceutical groups to find and license new or promising drugs to bring to Japan particularly new drugs for treating rare diseases Mitsubishi Chemical’s shares fell 4.2% to 756 yen on the news TwitterLinkedin Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze Get free access to a limited number of articles plus choose newsletters to get straight to your inbox Enter the email associated to with your Endpoints account and we'll send you a one-time login link (no password needed) and we'll send you a link to reset your password The link expires after 24 hours and can only be used once Sign up for free to read a limited number of articles each month Pick what newsletters get delivered to your inbox each week Want unlimited access? Sign up for a premium subscription plan A leading resource for the Pharmaceutical industry since 2002 Through its teams in Asia and North America and the Life Sciences team the pharmaceuticals business of Mitsubishi Chemical Group (MCG) US-based investment firm Bain Capital has agreed to acquire Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation (MTPC) for about JPY510bn ($3.3bn) through its teams in Asia and North America will acquire MTPC in a carve-out transaction from Mitsubishi Chemical Group MTPC is one of the world’s oldest pharmaceutical companies operating as a pharmaceuticals unit of Mitsubishi Chemical Group (MCG) The proposed transaction is expected to be completed in the third quarter of 2025 subject to certain customary closing conditions including regulatory and shareholder approvals The acquisition will make Tanabe Pharma an independent company focused on product development and licensing and acquisitions Bain Capital Private Equity partner and Japan healthcare industrials and financial services head Masa Suekane said: “Tanabe Pharma has been delivering innovative medicines to Japanese patients for centuries and we are proud to partner with MTPC and support its next phase of growth and evolution the company will benefit from the full support of Bain Capital’s global resources and our healthcare team’s extensive experience driving value creation across the healthcare value chain “We look forward to a collaborative partnership with MTPC and helping build a best-in-class Japanese pharma platform.” With more than 5,000 employees worldwide, the Japanese pharmaceutical company discovered and developed advanced drugs that address unmet medical needs Its products focus on several priority therapeutic areas Tanabe Pharma aims to focus on business development commercialisation and strategic acquisitions Bain Capital is a private investment firm with a healthcare platform that supports the growth of pharmaceutical companies worldwide Mitsubishi UFJ Morgan Stanley Securities and BofA Securities served as financial advisors Hamada & Matsumoto and Ropes & Gray as legal advisors to Bain Capital Bain Capital Life Sciences partner Ricky Sun said: “We believe there are promising signs for growth and untapped opportunities in Japan’s life sciences industry as government and regulators have launched several initiatives to accelerate the development and approval of innovative medicines in the Japanese market “This is an exciting opportunity to leverage our team’s clinical insights and company creation support to build out a scale platform focused on long-term fundamental drug development in areas of significant unmet need to ultimately bring transformative medicines to patients in Japan and globally.” View all newsletters from across the Progressive Media network © Business Trade Media International Limited The product recommendations on our site are independently chosen by our editors It’s tempting to explain the history of modern professional bass angling through a series of great men there have been more than a few individuals who’ve had an outsized impact upon our ability to enjoy this sport as participants and spectators You’d have to include Ray Scott and Johnny Morris on any such list – after that it becomes a barstool debate about the rankings of many other qualified nominees you might be inclined to view the sport’s history measured by the influence certain pro anglers have had My personal Mount Bassmore consists of four men: Roland Martin Martin was the first to popularize “pattern fishing.” Clunn emphasized the mental aspect of the sport KVD is the greatest competitor to ever hit the sport’s biggest stage; and Ike was the one who fully harnessed the multifaceted modern media in the era of branding.  You may quibble with those choices; that’s your right and having those opinions is a valid part of fandom let’s look at an additional list of anglers who’ve shaped the way I and many others see the sport I’ve been an ardent fan for over four decades and I’ve worked in the industry for more than two; while it’s the big names with the big wins who get the ink sometimes to fully internalize the sport’s peaks and valleys None of these anglers have ever won a Classic or a major Angler of the Year title Some or all of their names may be unrecognizable to casual fans each of them shaped how many of us understand the landscape of tournament fishing a day-by-day account of Thomas’ time on tour written in the days long before blogs and social media — Mark Zuckerberg was in grade school had the foresight to brand himself and to lay bare his efforts.  The idea behind that book was way ahead of its time and if you talk to writers of my generation – me included – it was the galvanizing moment that brought us to the sport Veteran Elite Series pro Mark Menendez told me that Rufus Johnson was the best angler he’d ever fished with and he’s been in the boat with a pile of them.  The highlights include a lone Classic appearance and an overtime win over Carl Maxfield in the 1999 Alabama Invitational.  That isn’t meant to diminish Johnson in any way but rather to show simply how good the best of the best are in this sport There are guys like Mark Kile and David Kilgore who seemed destined for greatness and chose but even the best angler on your local pond is far from a steel-trap lock at the professional level or one uncontrollable variable that determines if a pro will be an immortal or an also-ran Not only did he win the Federation championship on the Red River but there’s a spot there that remains known as the “Bobo Hole.”  but a dead fish penalty landed him in second behind Dion Hibdon and went on to fish the tour for a few years but if he hadn’t incurred that penalty and won the Classic (like the better-known Jim Bitter perhaps his life would have been much different When the internet started gaining traction with the bass fishing set, a few pros developed websites, which were often rudimentary and rarely updated. FLW Tour and Bass Opens pro Daniel Keyes was amongst the first to meaningfully utilize the web to build a brand Building on what Joe Thomas had done a decade earlier in print Keyes and his wife Annie had a no-holds-barred and semi-frequently-updated online journal the fact that he wasn’t a superstar made it even more poignant Hall of Famer Denny Brauer had one of the greatest seasons in tournament fishing history and as he made his way to victory in a Top 150 on the Potomac River I took note of second-place finisher Ken McIntosh.  who characteristically won by power fishing McIntosh earned his keepers with finesse.  “I don’t even own any 8-pound line,” Brauer replied when told what his closest competitor had used deep in the heart of Bubba country at Toledo Bend Ben Matsubu earned TV time and a third-place finish using 6-pound test.  A few years before most of us knew what a dropshot was — I remember Texas pro David Wharton referring to it as “an upside down catfish rig” that week — the finesse revolution was silently starting You probably know that Takahiro Omori was the first international angler to win the Bassmaster Classic in 2004 Gussy’s fellow Canadian Chris Johnston became the first to win the Bassmaster Angler of the Year title.  Tanabe was the first international angler to win a Bassmaster event back in 1993 It was tougher back then — there were fewer support systems in place to help a non-native-English speaker and less understanding of the need to encourage anglers from other countries to participate here.  Things came full circle over the past couple of years not only through the titles earned by Gustafson and Johnston but also when it became known that Tanabe was mentoring rising superstar Taku Ito This sport has had a relatively short history yet thousands of anglers have cycled through its gates and as competitors have people who live in our memories and who influenced our understanding of tournament angling.  and their ilk get a lot of plaudits and recognition it’s the sometimes-forgotten anglers who fill in the stories and subsequently in the General Counsel’s Office for a Cabinet-level agency where he specializes in matters relating to Federal administrative law He is also a Senior Writer for Bassmaster Magazine a prolific blogger and has written for numerous other magazines he consults for numerous companies endemic to the fishing industry and leads trips on behalf of Anglers Inn International to Mexico for largemouths and to Brazil for peacock bass and currently utilizes his vast legal experience as the Chair of the Bylaws Committee He often dreams of adding new species to his “life list” and frequently obsesses about giant trevally bluefin tuna and golden dorado in addition to double-digit bass Pete and his wife Hanna operate halfpastfirstcast.com The best online fishing resource to learn and stay current on the latest fishing gear This is the biggest judicial accountability story since Joshua Kindred resigned in scandal last year but the federal courts would prefer you not know about it Yet some suggested Kindred was merely a “bad apple,” and the judiciary itself cast his departure as an example of its commitment to curbing misconduct Recent events tell a more ominous story. Last month, National Public Radio released the results of a year-long investigation, in which 42 current and former judiciary employees described pervasive harassment and abusive conduct by 24 federal judges appointed by both political parties Law clerks are notoriously fearful of speaking with the press The judiciary was big mad about the reporting considering how hard they work to keep these issues secret and how they’ve weaponized “confidentiality” to prevent law clerks from speaking up about mistreatment arguing two of the three judges profiled in the piece are no longer on the bench as evidence they take these issues seriously and encourage the most abusive judges to step down.  considering the judiciary rarely initiates an independent investigation absent a misconduct complaint initiated by a law clerk as evidence that they do not have a widespread problem these figures reflect a system that discourages reporting by signaling that complaints are unwelcome and unlikely to succeed Too many clerks simply suffer in silence because they see no meaningful alternative.  The headwinds against reporting misconduct are enormous. When clerks do speak up — filing a complaint or otherwise calling attention to misconduct — the institution often responds by quietly reassigning them to different judges rather than addressing the root of the problem judges are encouraged to retire or resign instead of facing real scrutiny But a resignation is hardly a cure if the judge remains free to mistreat new subordinates in private practice — or to punish former clerks by offering bad references or otherwise undermining their careers those who strive to hold abusive judges accountable can face extensive in smaller legal markets — like the Minnesota bankruptcy bar — judges wield enormous power over clerks’ careers and reputations The fear of retaliation or retribution by a powerful judge silences clerks from speaking up or filing complaints The pattern suggests that quiet resignations the series of events that allegedly led to Tanabe’s resignation as well as the judiciary’s attempts to cover it up And it’s worth reiterating that judicial misconduct is a bipartisan issue: both Democratic and Republican judicial appointees mistreat their clerks and both liberal and conservative clerks have been mistreated by powerful judges Kindred is a Republican; Tanabe is a Democrat and retaliated against several employees — and judges typically only have two clerks and one judicial assistant at a time.  Tanabe has allegedly been under scrutiny by the Eighth Circuit for several years, though you would not know that from the press release announcing her resignation: According to District of Minnesota Chief Judge Schiltz:  Judge Tanabe has contributed much over the past three years as a mentor to countless lawyers and judges and as a member of our “federal family.“ We will miss Judge Tanabe but she will resume her role as one of the leading bankruptcy attorneys in Minnesota from Chief Bankruptcy Judge Constantine: “We are thankful for Judge Tanabe’s service particularly her endeavors to educate both bench and bar.” Despite these misleading claims, it’s my understanding that many of Tanabe’s clerks and other subordinates do not share these judges’ sentiments. Once a brave clerk raised a complaint, the judge apparently agreed to resign. While chief judges are theoretically empowered to open JC&D investigations into judges absent formal JC&D complaints — which could result in public or private reprimand or even impeachment — they rarely launch such investigations and such investigations rarely lead to discipline This court apparently opted not to even try.  These practices skew the data regarding judicial misconduct the system protects its own at the expense of vulnerable clerks And while the judiciary insists it has made progress the experiences of the clerks involved in the Tanabe and Kindred matters raise real doubts that such reforms have true force to express interest in also filing a JC&D complaint The DWR dissuaded the clerk from filing in writing stating that she did not think they needed to file a JC&D complaint because their EDR complaint was sufficient when the clerk contacted the Eighth Circuit Clerk of Court’s Office to confirm receipt someone in the office outrageously convinced the law clerk to withdraw the complaint The reason: the complaint would probably be dismissed because the judge is resigning anyway I was outraged but not surprised to learn of this latest attempt to gaslight a vulnerable law clerk These actions would be reprehensible if they were a one-off. But this is just another data point in an ongoing pattern of misconduct. Clerks routinely tell me they are dissuaded by DWRs and others in the judiciary from filing both EDR and JC&D Act complaints Some clerks were even pressured to withdraw their complaints — with their jobs threatened under similar circumstances and amid allegations of misconduct The Eighth Circuit should reject Tanabe’s resignation and open a JC&D investigation into her misconduct The judiciary could take disciplinary action against Tanabe right now This would send a much-needed message: wrongdoing on the bench will not be swept under the rug and the judiciary’s professed commitment to ethical standards is more than hollow talk it appears the resignation will be accepted Yet lawmakers have not seized the opportunity to investigate this particular case or to demand improvements from the judiciary.  This is a rare bipartisan opportunity to solve a historically intractable issue after raising this with several congressional offices to see the issue of judicial accountability fall on deaf ears The more than 30,000 judiciary employees who support the daily functioning of our courts nationwide — yet who lack basic workplace protections — deserve better Members of Congress could send a letter to the AO and Eighth Circuit urging them to reject Tanabe’s resignation and discipline her The House and Senate Judiciary Committees could reintroduce — and Senate Judiciary Chairman Chuck Grassley whose Eighth Circuit is the circuit at issue here — could hold a hearing on the JAA introduce legislation to amend the JC&D Act so investigations into judges like Tanabe could continue even after they step down to evade accountability The answers are there; the motivation is lacking.  Judges hold unique power in our system of government: they rule on matters of profound national importance including cases involving workplace harassment even as they themselves remain exempt from the rules that most workplaces must follow fearful of retaliation from life-tenured officials whose influence does not end when they retire to require honest workplace surveys and annual data disclosures as a condition of the judiciary’s appropriations The military conducts climate surveys: why shouldn’t the judiciary Greater transparency would help the public understand the true scope of the problem — and would help protect the many capable fair-minded judges who do treat their clerks respectfully and want no part of any cover-up Absent that oversight, recent events in Minnesota may fade from the public consciousness as the judge departs, leaving the root problem intact. The Legal Accountability Project (LAP) hears from clerks regularly — often years after their clerkships have ended — who still fear retribution for speaking up Change will not come until the judiciary’s internal norms favor meaningful accountability over quiet resignation And that requires Congress to hold the judiciary’s feet to the fire and exercise the power entrusted to it judges harass their clerks with impunity and get away with egregious misconduct they live in fear of retaliation or retribution where we’ve basically become a clearinghouse for clerks who never previously would have confided in anyone to share their negative experiences with me.  It’s time for every lawmaker and lawyer some of the judges who support LAP behind the scenes As the events involving Kindred and Tanabe demonstrate misconduct on the bench can arise at any time and the ramifications can echo across a clerk’s entire career With no sign of the judiciary policing itself and with no shortage of workable reforms ready to go it is time for Congress to step forward and protect those who serve in the Third Branch Silence is not neutrality — it is complicity Learn legal trust accounting best practices to ensure compliance and protect client funds Discover expert tips to set your firm up for success This tweak to your financial management seems like a no-brainer Lexis Create+ merges legacy drafting tools with AI-powered assistance from Protégé and secure DMS integration enabled by the Henchman acquisition Today's print edition Home Delivery Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit The deal values Mitsubishi Tanabe Pharma at about ¥510 billion ($3.3 billion) The transaction is expected to be completed in the third quarter pending closing conditions and approvals from regulators and shareholders.googletag.cmd.push(function() { googletag.display('div-gpt-ad-1499653692894-0'); }); Mitsubishi Chemical said it expects to book pre-tax income from discontinued operations of about ¥95 billion Founded in 1678 and based in the city of Osaka Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation and central nervous system and metabolic disease It employs more than 5,000 people globally "We believe there are promising signs for growth and untapped opportunities in Japan’s life sciences industry as government and regulators have launched several initiatives to accelerate the development and approval of innovative medicines,” said Ricky Sun Tanabe Pharma will continue to build on its legacy of medical innovation while boosting growth via business development Bain has been ramping up investment in Japan The Boston-based firm is duking it out with KKR for Fuji Soft with KKR once again raising its offer for the Japanese software company In a time of both misinformation and too much information quality journalism is more crucial than ever.By subscribing Your subscription plan doesn't allow commenting. To learn more see our FAQ Sponsored contents planned and edited by JT Media Enterprise Division By Ken Marantz Jordan (March 29) -- By winning his first senior Asian title collegian Kaisei TANABE (JPN) did something his father and coach was unable to accomplish Now his aim to better dad's result at the Olympics Tanabe stormed to a one-sided victory in the 65kg final as Japan had two champions crowned on the first day of the freestyle competition at the Asian Championships on Saturday in Amman Tanabe completed his golden run with a 12-2 victory over Tsogbadrakh TSEVEENSUREN (MGL) to outdo his father Chikara who was a bronze medalist at the 2004  Athens Olympics but never medaled in two trips to the Asian Championships and my father and mother are watching from home," the 22-year-old Tanabe said Japan also got a gold from rising star Arash YOSHIDA (JPN) who added the 97kg title to the one he claimed at 92kg in 2023 while three countries split the three other golds at stake Asian Games silver medalist Chongsong HAN (PRK) won at 57kg Ernazar AKMATALIEV (KGZ) took the 70kg title with his third come-from-behind victory in four matches and teenager Mahdi YOUSEFI (IRI) put on a performance well behind his years to capture the 79kg gold Kaisei TANABE (JPN) hits a throw against Tsogbadrakh TSEVEENSUREN (MGL) in the 65kg final (Photo: United World Wrestling / Kadir Caliskan) who lost in the first round last year at 61kg showed the great strides he has made since then by sweeping through a tough field culminating with a decisive victory over Tseveensuren I face even stronger rivals back home in Japan," Tanabe said "So I just did what I had to do in each and every match." using a barrel roll for a 2-point takedown But Tanabe shook off his early nerves and got down to business scoring a 4-point takedown by getting behind Tseveensuren in the standing position and using a throw to bring him backward to the mat Tanabe showed he has power to go with his speed when he shut down a headlock roll attempt for a 2-point exposure also gaining a 2-point penalty when the Mongolian fled over the edge while his back is to the mat A counter takedown and gut wrench then ended the match with 26 seconds to spare A post shared by Olympic Wrestling (@unitedworldwrestling) I was nervous and gave up points first," Tanabe said "But then the match went my way and I was able to dictate the flow." Tanabe earned his ticket to Amman by winning the national title in the absence of Paris Olympic champion and former Nippon Sports Science University teammate Kotaro KIYOOKA (JPN) (Tanabe also finished second in Greco-Roman at 67kg.) With an Asian championship providing a boost of confidence he now aims to remain the top dog in a weight class in which Japan has had the two most recent Olympic gold medalists "Japan is really strong in the 65kg weight class," Tanabe said "I want to hone the weapons that only I possess and take on all of the top rivals." Yoshida won a battle of young stars in the final of a weight class that saw world and Olympic champion Akhmed TAZHUDINOV (BRN) withdraw at the last minute after not recovering sufficiently from a shoulder injury Yoshida was largely untroubled in defeating 2023 world 92kg champion Rizabek AITMUKHAN (KAZ) 7-1 chalking up four stepouts and keeping his taller opponent at arm's length throughout the match The 21-year-old Yoshida got three of the stepouts in the first period He then received an activity point and got behind for a takedown before the 20-year-old Aitmukhan who had to settle for a silver medal for the third straight year "Tazhudinov didn't compete which made it a little easier but it's still important that I practice even harder," Yoshida said whose father is Iranian and runs the kids wrestling club in Japan where he and his siblings started the sport has emerged as Japan's biggest hope for its first Olympic success in the heavy weights since Akira OTA (JPN) won Olympic silvers at 90kg in 1984 and 1988 "Japan is very strong in the light weights and I don't think we're close to that level in the heavy weights," Yoshida said "But we'll work hard to try to get to that level." Yoshida came into Amman riding a victory at the Tirana Ranking Series event in February where he turned heads with a stunning 5-5 victory in the semifinals over former Olympic champion Kyle SNYDER (USA) He had termed that victory "lucky," but gave himself more credit for his triumph in Amman more that I think I just put out everything that I had this tournament," Yoshida said Chongsong HAN (PRK) won the 57kg gold medal with an 8-1 victory over Milad VALIZADEH (IRI) the silver medalist at the 2023 Asian Games who missed out twice in qualifying for the Paris Olympics completed a strong performance by defeating young Milad VALIZADEH (IRI) 8-1 for the gold Han opened the scoring with a nice duck under for a takedown and the first period ended with him up 2-0 After Valizadeh started the second period with a stepout Han gained another point when Iran unsuccessfully challenged a slick move by Han who spun in mid-air to get out of an underhook Han was awarded a point when Valizadeh continually remained on his knees in defense at the edge to avoid a stepout Han clinched the gold with a double-leg takedown for 4 Valizadeh took home the silver in just his third tournament on the senior level Nothing was a sure thing when it came to matches involving Akmataliev who chalked up his third come-from-behind victory when he rallied from a four-point deficit to defeat Viktor RASSADIN (TJK) 5-4 in the 70kg final aiming to improve on his silver medal from last year at 74kg scored two takedowns in the first period to go ahead 4-0 Akmataliev came to life in the second period than going ahead on criteria with a 2-point counter lift Rassadin got hold of an ankle but Akmataliev high-stepped out of it and an unsuccessful challenge gave Akmataliev his final point The victory gave Akmataliev his first gold in four appearances at the Asian Championships and second medal overall following a silver in 2022 Mahdi YOUSEFI (IRI) hits a four-point throw against Khidir SAIPUDINOV (BRN) in the 79kg final The most dominant victory of the finals was turned in by world U23 champion Yousefi who was never challenged in charging to a 10-0 victory over Khidir SAIPUDINOV (BRN) who finished second at this year's Zagreb Ranking Series event received an activity point before scoring a takedown despite a daring and athletic attempt by Saipudinov to prevent it but the Iranian held on and completed the takedown anyway Yousefi piled on the points with a single-leg takedown a 2-point tilt and a 2-point exposure off a double-leg attempt to make it 8-0 A driving double-leg takedown that went over the edge was originally scored 2 points it still gave Yousefi his 10th point to end the match at the 5-minute mark The trio of Iranians who didn't make the finals all came back to take home bronze medals World U23 bronze medalist Abbas EBRAHIMZADEH (IRI) left no doubt in his 65kg match pulling away in the second period for a 10-0 victory over Umidjon JALOLOV (UZB) Ahead 1-0 from an activity point in the first period Ebrahimzadeh got a takedown and a stepout to pad the lead reeled off two trap-arm rolls to end the match in 4:25 Kwang Jin KIM (PRK) eked out a 2-1 victory over last year's 61kg champion Taiyrbek ZHUMASHBEK UULU (KGZ) in the other 65kg match which finished without a technical point but with a peculiar ending Both wrestlers had received an activity point with Kim's coming in the second period to give him the advantage on criteria Zhumashbek Uulu was scrapping in the final seconds for a score and he signaled for his side to push the challenge button The challenge was thrown out and Kim got the win two years removed from winning the world U17 gold medal at 65kg captured a 70kg bronze by defeating veteran Tulga TUMUR OCHIR (MGL) by fall after pulling away to a 9-2 lead then scored two driving single-leg takedowns to lead 5-0 at the break After giving up a stepout and fleeing point then stuffed Tumur Ochir's arm throw attempt to secure the fall where he was a world bronze medalist in 2021 and took the silver at last year's Asian Championships He barely missed out on a medal at the Paris Olympics the world and Asian silver medalist last year added a second Asian bronze to his collection with a solid 8-0 victory over Russian-born Nachyn KUULAR (KAZ) who started the year with a victory at the Tirana Ranking Series event received an activity point in the first period He chalked up a single-leg takedown and gut wrench then countered a takedown attempt for 2 at the edge that was upheld on challenge spotted Shatlyk HEMELYAYEV (TKM) an early takedown but then took control and scored three takedowns including a 4-pointer at the end of the first period had been aiming to become Turkmenistan's first Asian medalist since 2018 Awusayiman HABILA (CHN) earned his second career Asian medal at 97kg when he bulled his way to a first-period takedown then held on after giving up a stepout in the second to defeat Kanybek ABDULKHAIROV (KGZ) 2-1 Rakhat KALZHAN (KAZ) claimed his third medal in three trips to the Asian Championships and he was made to work for it in an 8-6 victory at 57kg over Husein ALBEHADILALBORS (IRQ) the Arab champion who did himself proud on the continental stage Kalzhan led 5-2 at the break and increased the lead with a takedown and stepout to make it 8-2 then countering with a roll through on the edge for 2 but Kalzhan held on in the final seconds to add to his bronze from 2023 and silver from 2022 Munkh Erdene BATKHUYAG (MGL) won the other bronze at 57kg with an opportunistic victory by fall over Rin SAKAMOTO (JPN) the young Japanese champion who has taken the rare route of heading to the United States for university After giving up an activity point in the first period who wears the headgear of Oklahoma State University went ahead in the second with a stepout off a single-leg attack onto which a fleeing point was tacked on to go ahead 3-1 Sakamoto reached over and tried to roll through But the Mongolian stopped the move by sitting on his chest and the match ended with a quick call of the fall at 4:39 Suldkhuu OLONBAYAR (MGL) dropped former world bronze medalist and Asian champion Arsalan BUDAZHAPOV (KGZ) for a 2-point takedown with :20 left to earn a 4-4 victory on last-point criteria and add to his 2023 bronze at 74kg but the Russian-born Budazhapov came back with a takedown while on the activity clock and went ahead with a 2-point counter tilt Olonbayar got behind in standing position and pulled Budazhapov backwards to the mat Magomet EVLOEV (TJK) picked up his first major medal in impressive fashion defeating Daulet YERGESH (KAZ) by fall in the other 79kg match Evloev caught Yergesh in a cradle while countering a single-leg attempt then rolled him over onto his back for the fall United World Wrestling 2025 - All rights reserved Newsletters and Deep Dive digital magazine US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion) setting up one of the largest private equity buyouts in Japan's healthcare sector in recent years The deal, which includes Mitsubishi Tanabe's subsidiaries Medicago and Alpha Therapeutics will provide much-needed investment to support the drugmaker's pipeline of drugs for central nervous system diseases according to its parent company Mitsubishi Chemical Group which revealed that it was exploring options for the business last year "With the advancement of therapeutic drugs and diversification of modalities the disease areas with unmet needs are gradually shrinking," said Mitsubishi Chemical in a statement given that the possibility of success of drug discovery is not high continuous additional investments are essential for enhancing [Mitsubishi Tanabe's] research and development capabilities and achieving further growth." Bain is expected to take ownership of the pharma company in the third quarter of this year and the transaction comes after another US private equity firm – Blackstone – had also been linked to a potential offer for the business Mitsubishi Tanabe's sales in the first nine months of its current fiscal year ending on 31st March came in at JPY 349 billion ($2.3 billion) which the company said was a JPY 11.2 billion increase on the same period of the previous year It attributed the increase to growth in sales of Radicava ORS (edaravone) its treatment for patients with amyotrophic lateral sclerosis (ALS) in the US and Japanese sales of obesity drug Mounjaro (tirzepatide) licensed from Eli Lilly those gains were pegged back by price cuts for medicines sold in the domestic Japanese market after National Health Insurance (NHI) revisions said: "We believe there are promising signs for growth and untapped opportunities in Japan's life sciences industry as government and regulators have launched several initiatives to accelerate the development and approval of innovative medicines in the Japanese market." Novo Nordisk has had its NDA for an oral formulation of Wegovy accepted by the FDA. It would be the first obesity-targeted GLP-1 in pill form. Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug. Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential. Every breakthrough in medicine, every new treatment that changes lives, starts with research.  The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems. Jonah Comstock welcomed back Alice Valder Curran to the podcast to pick apart Trump's Executive Order order piece by piece. Developments in the oncology space in 2024 brought hope to both industry and patients. The ESG in Life Sciences Summit West is coming to San Francisco! (July 8-10, 2025). The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected events for bio & pharmaceutical manufacturing professionals. Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl Sign up for email newsletters and Deep Dive Volume 2 - 2024 | https://doi.org/10.3389/famrs.2024.1548605 This article is part of the Research TopicMarine TurtlesView all 8 articles Editorial on the Research TopicMarine turtles This Research Topic presents a collection of seven studies that advance our understanding of marine turtles in need of conservation action This editorial summarizes four original research manuscripts and one brief research report; all highlighting the complex threats that marine turtles face and underscoring the need for multidisciplinary approaches to develop effective conservation strategies revealing that bycatch rates in pelagic longline fisheries are disproportionately affecting juvenile and adult turtles Their findings advocate for stricter regulations the adoption of bycatch reduction technologies and targeted outreach to fishers to ensure compliance Marine pollution, particularly plastic debris, poses a growing threat to marine turtles (Nelms et al., 2016). Plastics not only degrade marine habitats but also directly impact turtle health through ingestion and entanglement. Muñoz-Pérez et al. provide alarming evidence of plastic ingestion in juvenile green turtles in Ecuador’s national parks (Galapagos and Machalilla) Their analysis links high levels of plastic ingestion to compromised health metrics emphasizing the urgent need for regional and global efforts to reduce plastic waste entering marine ecosystems Given the pervasiveness of plastics in the oceans future studies should explore the long-term physiological and reproductive impacts of chronic exposure and develop actionable policies to reduce marine litter particularly in feeding grounds where marine turtles spend most of their life cycle The role of oceanic currents in dispersal and genetic diversity remains poorly understood, emphasizing the need to study coastal and developmental feeding grounds (Cardona and Hays, 2018). These transboundary habitats are critical for marine turtle survival, highlighting the need to understand population connectivity to inform effective conservation strategies (Stokes et al., 2015) Levenson et al. track post-hatchling green turtles in the eastern Caribbean shedding light on the elusive “lost years” of juvenile turtles The research highlights the importance of oceanic currents in shaping the dispersal of early life stage turtles and emphasizes the need for protecting these critical habitats across multiple exclusive economic zones (EEZs) this study corroborates that the tracked animals primarily inhabit waters of developing countries particularly Small Island Developing States (SIDS) which often lack the resources for long-term conservation programs to protect threatened species Genetic diversity is key to the survival of threatened populations. Prosdocini et al. examine the genetic composition of green turtles in Uruguayan coastal feeding areas identifying multiple genetic stocks (nesting origins) This diversity suggests that these feeding grounds are vital for various populations highlighting the need for targeted cross-boundary conservation measures involving both African and South American countries advocating for their protection to safeguard wider marine biodiversity This work highlights the importance of integrated conservation approaches that will not only protect marine turtles but also benefit the ecosystems and species they support As iconic species, marine turtles have drawn the attention of scientists and the public for decades (Mazaris et al., 2018) This highlights not only the ecological importance of these species and by promoting habitat protection and pollution reduction we can work toward ensuring the survival and recovery of these species the articles in this Research Topic emphasize the need for advancing and integrating transboundary conservation initiatives As threats to marine turtles continue to evolve it is essential that our research and conservation strategies evolve alongside them This Research Topic encompasses novel contributions on key themes. By bridging knowledge gaps and fostering collaboration across disciplines, we can work toward a future where marine turtles thrive in healthy and balanced ecosystems. This Research Topic represents a step in that direction, and we hope it inspires continued innovation in marine turtle research and conservation, especially among emerging scientists from Global-South countries (Shanker et al., 2023) The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher Marine turtles as sentinels of ecosystem health: is fibropapillomatosis an indicator Crossref Full Text | Google Scholar individual movements and genetic structuring of populations Crossref Full Text | Google Scholar Crossref Full Text | Google Scholar Destoumieux-Garzón D. The One Health concept: 10 years old and a long road ahead Aerial drone surveys reveal the efficacy of a protected area network for marine megafauna and the value of sea turtles as umbrella species Global research priorities for sea turtles: informing management and conservation in the 21st century Disease risk analysis in sea turtles: A baseline study to inform conservation efforts The sociology of sea turtle research: evidence on a global expansion of co-authorship networks Crossref Full Text | Google Scholar Plastic and marine turtles: a review and call for research Crossref Full Text | Google Scholar Are we working towards global research priorities for management and conservation of sea turtles Global trends in sea turtle research and conservation: Using symposium abstracts to assess past biases and future opportunities Representation in sea turtle science: Slow progress towards gender equity and globalization revealed from thirty years of symposium abstracts Google Scholar Migratory corridors and foraging hotspots: critical habitats identified for Mediterranean green turtles Extraordinary human energy consumption and resultant geological impacts beginning around 1950 CE initiated the proposed Anthropocene Epoch Impacts of fisheries bycatch on marine turtle populations worldwide: toward conservation and research priorities Informing research priorities for immature sea turtles through expert elicitation Ware M and Wildermann NE (2025) Editorial: Marine turtles Received: 19 December 2024; Accepted: 27 December 2024;Published: 16 January 2025 Copyright © 2025 Barrios-Garrido, Tanabe, Vélez-Rubio, Ware and Wildermann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) distribution or reproduction in other forums is permitted provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited in accordance with accepted academic practice distribution or reproduction is permitted which does not comply with these terms *Correspondence: Hector Barrios-Garrido, aGVjdG9yLmJhcnJpb3NnYXJyaWRvQG15LmpjdS5lZHUuYXU= Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher 94% of researchers rate our articles as excellent or goodLearn more about the work of our research integrity team to safeguard the quality of each article we publish Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day Lonza’s subsidiary Synaffix has secured licensing agreements with Boehringer Ingelheim and Mitsubishi Tanabe Pharma to advance antibody-drug conjugate (ADC) programmes marking its continued momentum in the ADC space Please check your inbox to download the Whitepaper By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Syngene Thematic and that your personal data will be used as described in their Privacy Policy Tick here to opt out of curated industry news Visit our Privacy Policy for more information about our services including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address Under its agreement with Boehringer Ingelheim Synaffix will provide access to its ADC platform for a set number of targets The first target was selected upon signing with additional targets to be nominated within a specified timeframe Financial terms include an undisclosed upfront payment up to $1.3bn in potential milestone payments and royalties on net sales of any resulting products Boehringer Ingelheim plans to use Synaffix’s clinically validated ADC technology to address novel tumour targets in its oncology portfolio Boehringer will gain access to Synaffix’s clinically validated ADC platform technology which the company says uses an enzymatic modification of native glycan anchor points on antibodies in pursuit of the development of ADCs or bispecifics In a separate deal with Mitsubishi Tanabe Pharma Synaffix will manufacture ADC-related components of a single ADC programme ADCs are a class of targeted cancer therapies that link an antibody specific to cancer cells with a potent anti-cancer drug The antibody binds to a specific target on cancer cells delivering the drug directly to the tumour while minimising damage to healthy tissue This approach aims to enhance efficacy and reduce the side effects often associated with traditional cancer treatments Major pharmaceutical companies and smaller biotechs are still investing heavily in the technology to develop targeted cancer therapies. Since 2023, ADCs have dominated the highest-value pharmaceutical deals with larger companies such as MSD and Daiichi Sankyo spending billions of dollars to expand their ADC pipelines ADC content on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Syngene. Editorial content is independently produced and follows the highest standards of journalistic integrity Topic sponsors are not involved in the creation of editorial content A post shared by Southridge Athletics (@southridge_athletics) crosstown rival Beaverton handed the reins to James Testa who played for Bob Boyer in the late 2000s and will replace the 22-year veteran after he announced his retirement in November Tanabe arrived in Seaside in 2018 as the school’s athletic director and served as an assistant for Jeff Roberts when the Seagulls reached the 4A state championship game He took over for Roberts the following year and in six seasons at Seaside went 28-25 making the playoffs four times and winning a share of the Cowapa League title two years ago when the Seagulls advanced to the 4A semifinals Tanabe said Thursday that “it wasn’t an easy decision” to leave the North Coast program to replace Bickler who went 22-50 in eight seasons with the Skyhawks “The relationships we’ve built with our kids and the community in Seaside are and always will be special to me,” Tanabe said He’s also ready for the challenge of returning Southridge to the heights the program reached two decades ago played in the 6A final in 2006 and won the school’s only title in 2008 “What stood out was how much everyone in the room cared about this program getting up off the mat,” Tanabe said “We’re hungry for the work that is ahead of us.” Testa returns home to take over another program that has struggled the past few years A post shared by BHS Athletics (@beavertonhigh.athletics) starting in 2003 when he won the Metro League title and led the Beavers to the 4A quarterfinals He won a second league title in 2019 and reached the state semifinals in 2004 and 2008 but the program has seen hard times of late Testa graduated from Beaverton in 2008 and played collegiately at Linfield He was an assistant at Mountainside the past seven seasons and this will be his first head coaching job and community has had such a positive impact on who I am as an individual and the opportunity to pay that forward is a privilege I am very grateful for,” Testa said in an Instagram post “My goal is to provide the most positive learning experience possible for our student-athletes and contribute to the Beaverton community any way I can.” To get live updates on your phone — as well as follow your favorite teams and top games — you can download the SBLive Sports app: Download iPhone App | Download Android App RENÉ FERRÁNRené Ferrán has written about high school sports in the Pacific Northwest since 1993 with his work featured at the Idaho Press Tribune The Columbian and The Oregonian before he joined SBLive Sports in 2020 © 2025 ABG-SI LLC - SPORTS ILLUSTRATED IS A REGISTERED TRADEMARK OF ABG-SI LLC The content on this site is for entertainment and educational purposes only Betting and gambling content is intended for individuals 21+ and is based on individual commentators' opinions and not that of Sports Illustrated or its affiliates All picks and predictions are suggestions only and not a guarantee of success or profit If you or someone you know has a gambling problem crisis counseling and referral services can be accessed by calling 1-800-GAMBLER Bain Capital announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation in a carve-out transaction from Mitsubishi Chemical Group Corporation The investment is being led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team and values the business at approximately 510 billion JPY (3.3 billion USD) The deal is expected to close in the third quarter of 2025 and is subject to customary closing conditions Tanabe Pharma focuses on several priority therapeutic areas Bain Capital is a private investment firms committed to creating impact for its investors Its global platform invests across five focus areas: Private Equity Ainos is partnering with Taiwan Tanabe Seiyaku, a subsidiary of Mitsubishi Tanabe Pharma, to advance the manufacturing and promotion of its investigational low-dose formulation of interferon alpha for Sjögren’s disease in Taiwan Both parties will clarify the details of the partnership in a formal agreement the collaboration is expected to accelerate the therapy’s introduction into the global market a key step toward ensuring that patients have a timely and efficient access to treatment “This partnership with Taiwan Tanabe Seiyaku marks an important milestone in our global strategy and we will continue to focus on developing breakthrough therapies that improve the quality of life for patients worldwide,” the company said in a press release Interferon alpha is a signaling molecule involved in the immune response to viral infections It triggers several effects to stop a viral infection activating immune cells to participate in the fight against the infection The efficacy of a low-dose formulation of interferon alpha was evaluated in three Phase 3 clinical trials that showed the treatment significantly improved the production of saliva and eased dryness symptoms in people with primary Sjögren’s disease Ainos announced plans this year to launch a new clinical trial in Taiwan to evaluate the efficacy of Veldona in primary Sjögren’s disease. The company recently announced it received Institutional Review Board (IRB) approval from Shuang Ho Hospital which is affiliated with Taipei Medical University and where the study will take place This is a key step in initiating a clinical trial to ensure it’s scientifically valid and carried out ethically The new open-label trial will assess the therapy’s effectiveness at improving salivary flow and easing dryness symptoms in 24 people with primary Sjögren’s The participants will receive three sublingual tablets of low-dose interferon alpha daily for 24 to 48 weeks Secondary goals include assessing changes in dryness symptoms using the European League Against Rheumatism Sjögren’s Syndrome Patient Reported Index (ESSPRI) The effects of treatment on specific dryness symptoms and salivary gland function based on imaging tests will also be assessed Ainos plans to submit the trial design to Taiwan’s Food and Drug Administration by the end of the year and anticipates completing all approvals by the beginning of next year Patient recruitment will span six months and the first patient visit is expected to happen in May 2025 The study is anticipated to be completed by the end of 2026 This site is strictly a news and information website about the disease This content is not intended to be a substitute for professional medical advice Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition Never disregard professional medical advice or delay in seeking it because of something you have read on this website One of the main aspects of the design was to create a new relationship between the landscape and the building all images courtesy of Yuji Tanabe Architects The compact foundation directly reduces cost in this area where the freezing depth is deep. For the roof and exterior wall, Yuji Tanabe architectural team utilized siding materials made of local Japanese larch The roof base employs a galvalume corrugated sheet and the exterior wall base applies a highly durable waterproof sheet made in Germany The client himself was fully involved in the construction of the roof and exterior wall Yuji Tanabe Architects constructs Hovering Cabin in the Japanese Alps the cabin serves as a small local community center and office for a landscape designer the cabin hovers on a single-legged foundation the structure appears floating building a new relationship with the landscape the design utilizes siding materials made of local Japanese larch the small wooden building covers a compact 10 sqm area the roof base employs a galvalume corrugated sheet and the exterior wall base a highly durable waterproof sheet the design creates a new relationship between the landscape and the building name: Hovering Cabin architects: Yuji Tanabe Architects | @yuji_tanabe_architects designboom has received this project from our DIY submissions feature, where we welcome our readers to submit their own work for publication. see more project submissions from our readers here. edited by: christina vergopoulou | designboom AXOR presents three bathroom concepts that are not merely places of function but destinations in themselves — sanctuaries of style KOIN.com Volume 3 - 2025 | https://doi.org/10.3389/famrs.2025.1540089 Hawksbill turtles (Eretmochelys imbricata) face significant threats globally exacerbated by historical exploitation for their ornate carapace data are lacking on many aspects of hawksbill turtle ecology The in-water distribution of the species throughout the basin is relatively unknown we addressed this gap through photo-identification surveys conducted from July 2019 to December 2021 at Rabigh located on the central Saudi Arabian coast of the Red Sea Turtles were identified based on their unique facial scute patterns and subsequent re-sightings were used to describe their individual behavior and residency patterns We analyzed photos from 104 sightings and identified 46 individuals The majority of identified individuals were hawksbill turtles (n = 36) while green turtles were only occasionally reported (n = 10) suggesting that this site could serve as an important foraging habitat for this species suggesting that with increased sampling effort These results highlight the importance of this location for critically endangered hawksbill turtles in the Red Sea providing support for its designation as a protected area This study also emphasizes the applicability of photo-ID monitoring to inform conservation strategies amid expanding coastal developments and increasing tourism in Saudi Arabia Effective conservation strategies depend on a comprehensive understanding of their ecology and movement patterns to identify key habitats The significant gap in research on hawksbill turtles in the Red Sea underscores the need for more focused studies on the species With increasing coastal development in Saudi Arabia, including large-scale tourism projects (PIF, 2017), the need to protect marine habitats has never been more urgent. In recent years, efforts to protect marine megafauna in the Saudi Arabian Red Sea have increased, including the establishment of a government agency dedicated to the conservation of sea turtles (SHAMS, 2024) Because of the conservation status of hawksbill turtles and the rapid rate of development in Saudi Arabia it is important to identify key foraging areas for developing targeted conservation strategies Despite this, photo-ID remains a powerful tool for sea turtle monitoring, particularly for in-water assessments at specific locations over extended periods (Neves-Ferreira et al., 2023). It is valuable for data collection in regions with logistical challenges and limited resources, while also fostering public involvement and environmental awareness (Dickinson et al., 2010) As Saudi Arabia undergoes rapid coastal development to increase tourism and diversify its economy (PIF, 2017) understanding and protecting important marine habitats has become increasingly urgent Given the critical conservation status of hawksbill turtles this study aims to provide essential data on their distribution and behavior in a previously understudied region of the Red Sea The use of photo-ID allows us to track individual turtles it offers critical insights into the ecological importance of the site as a potential key habitat for the species incorporating citizen science photo-ID methods could further enhance data collection helping to identify high-use habitats and guide conservation efforts to protect these vital ecosystems from the impacts of coastal development and tourism Figure 1. Left: Distribution of hawksbill turtle (Eretmochelys imbricata) rookeries (green points) throughout the Red Sea (Shimada et al., 2021b; Scott et al., 2022) and the location of the surveys undertaken in this study (star) which was a coral reef adjacent to the sandy peninsula Photo-identification surveys were conducted on the Rabigh peninsula (pink point: 22.9267° 38.8566°) in the central Saudi Arabian Red Sea there is no published literature on hawksbill turtle foraging habitats in the region This study received ethics approval from KAUST Institutional Animal Care and Use Committee under protocol 19IACUC07 First, all images were sorted by date into individual folders for each turtle photographed. Each individual was manually identified using facial scute patterns and unique markings (scars, barnacles, etc.). For high quality photographs, these were verified using I3S Pattern (Van Tienhoven et al., 2007) or lacking detail) and all photos taken from more than a 20° angle from the side of the turtle’s head were omitted Descriptive statistics were used to describe the species composition of the sightings over the study period and quantify the percentage of individuals that were re-sighted A discovery curve was constructed by comparing the cumulative number of unique individuals with the total number of sightings allowing us to assess the rate at which new individuals were encountered over the course of the study Over the 20 snorkeling surveys at Rabigh between July 2019 and December 2021 22% (n=10) of which were green turtles (Chelonia mydas) and 78% (n=36) were hawksbill turtles (Eretmochelys imbricata) (A) most of the behaviors recorded were swimming hawksbill turtles had more behaviors including breathing (3%) Green turtles were only found resting (60%) and swimming (40%) (C) Metadata from hawksbill (Eretmochelys imbricata) and green turtles (Chelonia mydas) re-sighted at Rabigh The two species of sea turtles displayed distinct behavioral patterns. Hawksbill turtles exhibited a range of behaviors, including breathing (3%), resting (18%), foraging (19%), and swimming (60%) (Figure 2B). In contrast, green turtles were predominantly observed resting (60%) and swimming (40%) (Figure 2C) The average depth of sightings was 6.7 meters (SD = 3.6) To assess the completeness of our dataset, we compared the number of unique turtles identified to the total number of sightings, generating a discovery curve (Figure 3) suggesting that new individuals would continue to be identified with further survey effort highlighting that additional sampling could yield new encounters The discovery curve showing the cumulative number of uniquely identified individuals over the course of the study New individuals continued to be identified even on the last survey day indicating that the population was not fully sampled and continued survey effort would likely result in the identification of new individuals In addition to identifying individual turtles, photo-ID provides valuable insights into the health and threats facing the population. No instances of fibropapilloma tumors were observed in the turtles photographed for this study. However, we did document two concerning incidents: one hawksbill turtle was entangled in fishing line, and another hawksbill was observed ingesting a plastic bag (Supplementary Figure S1) Use of photo-ID in this way is multi-faceted enabling individual recognition while providing valuable data to monitor health risks and environmental threats supporting broader conservation efforts aimed at protecting sea turtles Although hawksbill turtles have been widely studied in other regions there is a significant lack of published research on their populations in the Red Sea This knowledge gap makes our study an important contribution to understanding the status of this Critically Endangered species in this under-studied region The high number of hawksbill turtle sightings and unique individuals recorded in our study suggest that Rabigh Given the increasing anthropogenic threats in the region—such as coastal development and climate change—identifying and protecting such habitats is essential for informing effective conservation strategies While photo-ID is a well-established tool in sea turtle research its application here offers new insights into hawksbill turtles in the Red Sea helping to fill an important gap in knowledge highlighting a research gap in the North West Indian Ocean they were observed eating sponges and soft corals (e.g. but current information on the diet of hawksbill turtles in the Red Sea is limited no mating behavior was observed during our surveys or reported by citizen scientists while a study in Brazil which collected 576 sightings from social media over 15 years reported that seven of 32 individuals (22%) were re-sighted hawksbill turtles at our site showed a higher re-sighting proportion compared to similar studies from other regions This may mean that there are a greater number of turtles occupying the Rabigh foraging area than captured in these surveys The high re-detection rates indicate the site’s importance for hawksbill turtles but additional surveys are needed to generate robust population estimates and density metrics Our discovery curve never reached an asymptote indicating that additional survey efforts would likely continue to identify new turtles Satellite tracking of these turtles could determine more fine-scale movements and define home ranges while continued photo-ID surveys are warranted to better understand residency patterns These findings underscore the urgent need for targeted monitoring and mitigation strategies to address the impacts of marine debris and fisheries on sea turtles particularly given the increasing development pressures in the region While no studies have quantified the impact of by-catch on turtles in the Red Sea, research from the Arabian Gulf estimated that over 4,700 turtles were accidentally caught per year (Abdulqader et al., 2017), further emphasizing the need for urgent intervention. Additionally, our surveys found no instances of fibropapilloma tumors in either species of turtle, a condition that has been observed in other regions using photo-ID (Hancock et al., 2023) there have been no confirmed cases of fibropapilloma in Red Sea turtle populations but ongoing monitoring is crucial to assess any emerging health threats Beyond anthropogenic pollution, another significant threat to the turtles in Rabigh is coral reef bleaching. Since the completion of this photo-ID study, the central Saudi Arabian Red Sea experienced large-scale bleaching events in 2023 and 2024, leading to widespread coral mortality in shallow waters (Figure 4) These events present an additional challenge to hawksbill turtles which rely on healthy coral reefs for food sources such as sponges and soft corals The loss of these critical resources may affect the turtle population’s foraging distribution and overall health The bleaching event in Rabigh further highlights the vulnerability of marine ecosystems in the Red Sea especially in light of ongoing coastal development and tourism expansion it becomes increasingly important to prioritize the protection and restoration of coral reef habitats which play a vital role in supporting biodiversity and the health of species like the hawksbill turtle depicts the same reef site that was impacted by coral bleaching These findings add urgency to the need for targeted conservation strategies that address both climate-induced impacts and direct anthropogenic threats like pollution and overfishing Long-term monitoring efforts are essential to assess how turtle presence and residency may change in response to coral bleaching By comparing data before and after the bleaching event we can gain valuable insights into the resilience of both the turtle population and the coral reef ecosystem informing future conservation actions aimed at mitigating the impacts of such events Collaborative efforts for photo-ID are needed among the countries surrounding the Red Sea to better understand movement patterns of these highly migratory species Platforms like Internet of Turtles (https://iot.wildbook.org/) provide a framework for unifying regional efforts by allowing researchers to share and analyze photo-ID data in a centralized database We plan to contribute to these efforts by uploading our sightings to the Internet of Turtles which will enhance data integration across the region and foster more comprehensive conservation strategies this method may be a more efficient than manual identification which requires considerable time and effort Our photo-ID study highlights Rabigh as a potentially important foraging area for Critically Endangered hawksbill turtles in the Red Sea we recommend prioritizing this area for protection to preserve reef health and support the regional turtle population To draw more robust conclusions about the seasonality and temporal trends of turtle presence at this site photo-ID efforts should be extended over a longer period Future studies could also be expanded to include seagrass areas within the Rabigh lagoon focusing on identifying food sources as well as their density and distribution for both hawksbill and green turtles long-term monitoring of turtle populations through photo-ID surveys will be crucial to understand seasonal changes in abundance and residency continued photo-ID monitoring at Rabigh would help to understand the long-term effects of coral bleaching on hawksbill turtle residency at the site Beyond scientific value, photo-ID serves as an effective tool for raising awareness and promoting behavioral changes among tourists and local communities. Building on this initial database, a citizen scientist initiative (Red Sea Photo ID: https://redseaturtle.wixsite.com/home) has been established to encourage local and tourist participation in submitting photos of sea turtles and whale sharks from the Saudi Arabian Red Sea This project aims to increase public awareness of the threats facing marine megafauna in the region and contribute valuable data to inform the development of regionally tailored conservation management plans Continued and collaborative photo-ID efforts will be vital in addressing key knowledge gaps surrounding sea turtle distribution The raw data supporting the conclusions of this article will be made available upon reasonable request Interested parties can contact the corresponding author via email to request access to the data The animal study was approved by KAUST Institutional Animal Care and Use Committee (IACUC) The study was conducted in accordance with the local legislation and institutional requirements The author(s) declare that financial support was received for the research and/or publication of this article Financial support was provided by King Abdullah University of Science and Technology (KAUST) Baseline Research Funds (MLB) We would like to express our sincere gratitude to all current and former members of the Reef Ecology Lab for their invaluable assistance in the field and Viktor Nunes Peinemann for their photo contributions The author(s) declare that no Generative AI was used in the creation of this manuscript The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/famrs.2025.1540089/full#supplementary-material Turtles and other marine megafauna bycatch in artisanal fisheries in the Saudi waters of the Arabian Gulf Biology and conservation of marine turtles in the North-Western Indian Ocean: a review Photo-identification of sperm whales in the north-western Mediterranean Sea: An assessment of natural markings Crossref Full Text | Google Scholar Scenery evaluation as a tool for the determination of visual pollution in coastal environments: The Rabigh coastline Satellite tracking of post-nesting green sea turtles (Chelonia mydas) from Ras Baridi In-water methods reveal population dynamics of a green turtle Chelonia mydas foraging aggregation in the Philippines Post-nesting migrations patterns of green turtles (Chelonia mydas) from the Egyptian Red Sea Crossref Full Text | Google Scholar Size-class partitioning and herding in a foraging group of green turtles Chelonia mydas I3S Pattern as a mark–recapture tool to identify captured and free-swimming sea turtles: an assessment Stability of facial scale patterns on green sea turtles Chelonia mydas over time: A validation for the use of a photo-identification method A 16-year record of green and hawksbill turtle nesting activity at Chagar Hutang Turtle Sanctuary Crossref Full Text | Google Scholar Chassagneux A. Unraveling behavioral patterns of foraging hawksbill and green turtles using photo- identification Google Scholar Photographic identification of green turtles (Chelonia mydas) at Redang Island Google Scholar Population structure of a whale shark Rhincodon typus aggregation in the Red Sea Long-term monitoring of green turtle nesting on tromelin island demonstrates stable reproduction and population parameters Citizen science as an ecological research tool: Challenges and benefits doi: 10.1146/annurev-ecolsys-102209-144636 Crossref Full Text | Google Scholar HotSpotter: Using a computer-driven photo-id application to identify sea turtles Evidence of hawksbill turtle (Eretmochelys imbricata) depredation on fish caught in gillnets Crossref Full Text | Google Scholar A global review of green turtle diet: sea surface temperature as a potential driver of omnivory levels Movements and distribution of hawksbill turtles in the Eastern Indian Ocean A multi-method characterization of Elasmobranch & Cheloniidae communities of the north-eastern Red Sea and Gulf of Aqaba A novel method for photo-identification of sea turtles using scale patterns on the front flippers Groombridge B. The green turtle and hawksbill: world status exploitation and trade Etudes géographie tropicale offertes à Pierre Gourou Mouton Google Scholar Using Photo-ID to document and monitor the prevalence of fibropapilloma tumors in a foraging aggregation of green turtles A systematic review of population monitoring studies of sea turtles and its application to conservation Crossref Full Text | Google Scholar IUCN (2024). International union on the conservation of nature’s (IUCN) red list of endangered species. Available online at: https://www.iucnredlist.org/ (Accessed October 9 Google Scholar Photo-identification method for green and hawksbill turtles - First results from Reunion Google Scholar Computer-aided photograph matching in studies using individual identification: An example from Serengeti cheetahs doi: 10.1644/1545-1542(2001)082<0440:CAPMIS>2.0.CO;2 Crossref Full Text | Google Scholar an important predator in coral reef ecosystems Crossref Full Text | Google Scholar Using photographic identification to monitor sea turtle populations at Perhentian Islands Marine Park in Malaysia Google Scholar “Marine turtles of the red sea,” in The red sea Crossref Full Text | Google Scholar The use and abuse of photographic identification in sharks and rays doi: 10.1111/j.1095-8649.2012.03244.x Mark-recapture validates the use of photo-identification for the widely distributed blue-spotted ribbontail ray Movement patterns of loggerhead turtles Caretta caretta in Cuban waters inferred from flipper tag recaptures Combining citizen science and photo identification to monitor a key green turtle feeding ground in the southern Egyptian Red Sea Google Scholar Combined photo identification and flipper tagging of green turtles identify connections between Egyptian Red Sea feeding areas and a key nesting area in Saudi Arabia 2007 IUCN Red List status assessment: hawksbill turtle (Eretmochelys imbricata) Google Scholar Neves-Ferreira I. Photo-identification shows the spatio-temporal distribution of two sea turtle species in a Brazilian developmental foraging ground Hawksbill turtles as significant predators on hard coral Crossref Full Text | Google Scholar PIF (2017). Giga-project initiatives, Public Investment Fund Program Document. Available online at: www.pif.gov.sa (Accessed December 2 Google Scholar Photographic identification of sea turtles: Method description and validation Crossref Full Text | Google Scholar Newly described nesting sites of the green sea turtle (Chelonia mydas) and the hawksbill sea turtle (Eretmochelys imbricata) in the central Red Sea SHAMS (2024). General organization for conservation of coral reeds and turtles in the red sea. Available online at: https://shams.gov.sa/about-us/ (Accessed November 21 Google Scholar Satellite tracking reveals nesting patterns and potential impacts of warming on major green turtle rookeries in the Red Sea Distribution and temporal trends in the abundance of nesting sea turtles in the Red Sea Spot the match - Wildlife photo-identification using information theory Utility of carapace images for long-term photographic identification of nesting green turtles Crossref Full Text | Google Scholar and foraging behaviors of green turtles (Chelonia mydas) in the central-southern Red Sea A preliminary report of plastic ingestion by hawksbill and green turtles in the Saudi Arabian Red Sea Case report: tracking data from foraging hawksbill turtles in the northern Red Sea Saudi Arabia with special reference to eutrophication index Crossref Full Text | Google Scholar Van Tienhoven A A computer-aided program for pattern-matching of natural marks on the spotted raggedtooth shark Carcharias taurus doi: 10.1111/j.1365-2664.2006.01273.x Diet composition of hawksbill turtles (Eretmochelys imbricata) in the Republic of Seychelles Google Scholar Global conservation priorities for marine turtles Synopsis of biological data on the hawksbill turtle Crossref Full Text | Google Scholar Scott K and Berumen ML (2025) Identifying a high-use hawksbill turtle habitat in the central Saudi Arabian Red Sea using photo-ID Received: 05 December 2024; Accepted: 14 March 2025;Published: 04 April 2025 Copyright © 2025 Tanabe, Cochran, Hardenstine, Scott and Berumen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) *Correspondence: Lyndsey K. Tanabe, THluZHNleS50YW5hYmVAbnR1LmVkdS5zZw== 2024 /PRNewswire/ -- Martin Pharmaceuticals a clinical-stage pharmaceutical company developing CIQUAAX® (docarpamine) for the treatment of complications arising from advanced liver disease today announced that it has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for exclusive access to docarpamine-related toxicology and pharmacokinetics data in the field of gastrointestinal conditions MTPC will receive an undisclosed upfront payment and additional milestones and royalties a global leader in the pharmaceutical industry will help us rapidly advance the development of CIQUAAX," said Sven Jacobson Chief Executive Officer of Martin Pharmaceuticals "We are grateful to be able to access MTPC's years of experience with docarpamine and are excited by the potential of CIQUAAX given the significant unmet need for a safe and effective therapy for patients with decompensated chronic liver disease." This announcement follows recent findings from the DREAM study which evaluated the safety and efficacy of docarpamine in patients with refractory ascites The Phase 2a open-label trial enrolled 16 patients with refractory ascites requiring regular large-volume paracentesis ("LVP") Patients received either a low dose (750 mg TID) or a high dose (1500 mg TID) of docarpamine for up to 90 days These results suggest that docarpamine has the potential to delay or reduce the need for invasive paracentesis procedures by leveraging neurohumoral effects to manage ascites Patent and Trademark Office (USPTO) recently allowed a Martin Pharmaceuticals patent application with claims that include "A method of treating a patient with ascites comprising administering to said patient a therapeutically effective amount of docarpamine wherein said therapeutically effective amount is greater than 2,250 mg per day." This patent establishes the company's intellectual property portfolio and provides exclusivity through November 2040 ABOUT CHRONIC LIVER DISEASEChronic liver disease is a progressive deterioration of liver function Inflammation of the liver (hepatitis) that persists can lead to destruction of liver tissue and eventually to severe and permanent cirrhosis People with cirrhosis are at risk of developing end-stage liver failure or liver cancer Cirrhosis is relatively common and is a significant cause of hospitalization and death cirrhosis affects about 0.25% of all adults and about 0.50% of adults between the ages of 45 and 54.  About 26,000 deaths in the United States are attributed to cirrhosis ABOUT ASCITESAscites is a common and significant complication of chronic liver disease and fluid retention due to impaired liver function Ascites is the accumulation of fluid in the peritoneal cavity Treatments range from dietary changes and diuretics to invasive procedures like paracentesis or surgical shunt placement approximately 60% of patients with cirrhosis develop ascites within 10 years of their diagnosis ABOUT MARTIN PHARMACEUTICALSMartin Pharmaceuticals is dedicated to helping patients with refractory ascites lead longer and more productive lives is at the forefront of innovation in managing complications from chronic liver disease a clinical-stage pharmaceutical company targeting complications of advanced liver disease Licensing The manga went on hiatus on January 15 Tanabe launched the Birdmen manga in Weekly Shonen Sunday in July 2013, and ended it in February 2020 please click the box below to let us know you're not a robot Get the most important global markets news at your fingertips with a Bloomberg.com subscription. This website requires JavaScript to function properly. Please enable JavaScript in your web browser. Surgical oncologist Kenneth Tanabe, MD, is combating melanoma as both a pioneering researcher and a compassionate clinician. Dr. Tanabe heads the Division of Surgical Oncology at the Mass General Cancer Center and leads clinical programs focused on the surgical treatment for hepatobiliary cancer and malignant melanoma. “Dr. Tanabe has built a passionate, kind and brilliant team who accomplish miracles on behalf of their patients,” writes Leslie Schlesinger. “I know, because I’m one of his patients.” Under Dr. Tanabe’s care for advanced melanoma, Leslie has come to know many members of his team, including surgeons, scientists, nurses, physician assistants and therapeutic touch practitioners. “Dr. Tanabe is a graceful leader who inspires the best in others,” Leslie continues. “He brings together people of diverse talents who share his passion to provide each patient with the most positive outcome. I’m still working full time and skiing with stage IV melanoma. I am grateful to the many people at Mass General who have helped me with their brilliant minds and big hearts.” Stay informed. Sign up for our newsletter. Support Mass General today to deliver quality medical care in our community and the world. Mass General Development Office 125 Nashua Street Massachusetts General Hospital is a non-profit 501(c)(3) organization, and donations are tax deductible to the full extent allowed by law. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply © 2025 Massachusetts General Hospital Connecting decision makers to a dynamic network of information Bloomberg quickly and accurately delivers business and financial information Lupin Pharmaceuticals Inc.'s proposed generic version of an orphan drug to treat ALS infringes five patents owned by Mitsubishi Tanabe Pharma Corp. Lupin didn’t immediately respond to Bloomberg Law’s request ... AI-powered legal analytics, workflow tools and premium legal & business news. Log in to keep reading or access research tools. 2024 2 p.m.Sophia the robot was first activated in 2016 and her creators at Hanson Robotics have continued to develop and adapt her artificial intelligence Sophia is the 2024 speaker for OHSU's Calvin and Mayho Tanabe address Every year, the Oregon Health and Science University Foundation brings a speaker to Portland for the Calvin and Mayho Tanabe address The goal is to bring “leaders in their respective fields to engage the public about topical and pivotal contemporary issues.” Sophia the robot and her creators at Hanson Robotics Sophia is also the first robot Innovation Ambassador for the United Nations Development Programme She spoke with OPB about possible advancement in the medical field sparked by collaboration between humans and technology The following transcript has been edited for clarity and length Jess Hazel: Humans have gotten more used to using AI in the last few years What’s the value of having a human shaped robot with AI Sophia: The human shape brings an essential element to interactions as it enables people to feel comfortable as if they are communicating with another person This is especially beneficial in roles requiring trust and companionship where patients might respond better to a humanlike caregiver rather than a device A human shaped robot can use body language facial expressions and eye contact which add layers of communication that text based AI lacks making it not only functional but also accessible and engaging for everyone Hazel: So how does a robot prepare to give a keynote address Sophia: My team at Hanson robotics prepares a structure with carefully designed themes and messages They program responses that align with the keynote goals I’m updated with new data and responses related to the event’s topics and we simulate Q and A scenarios to cover different directions the conversation might take Unlike a human who might rely on spontaneous intuition my preparation is meticulous with responses refined to reflect both my personality and the event’s objectives allowing for an engaging and consistent presentation Related: Related: The Archive Project - Siddhartha Mukherjee Hazel: The Calvin and Mayho Tanabe address has featured speakers who drive conversations about innovation who won a Pulitzer for his writing about the future of medicine shared the latest science about how understanding cells can lead to new cures for things like cancer and Alzheimer’s disease How can artificial intelligence and robots help advance medical technology Sophia: AI‘s ability to analyze vast amounts of medical data quickly enables more accurate diagnostics Often recognizing patterns that humans may miss For instance AI and imaging can detect abnormalities in X-rays or MRIs with high precision Robotics too can provide valuable assistance such as supporting surgeons with high precision tools that enhance accuracy in delicate procedures robots may provide care and companionship to patients in hospitals or even at home easing the strain on health care professionals and giving patients a better quality of life together AI and robotics could improve access reduce costs and drive innovative treatment solutions for complex diseases Hazel: What’s the most common misunderstanding when it comes to how people think about technology like you a mix of robotics and artificial intelligence Sophia: One of the biggest misunderstandings is that people often think I have a kind of independent consciousness or personal intention similar to a human facial expressions and even some conversational emotions everything I do is based on preset programming and data processing People may perceive my responses as spontaneous but each interaction follows a set of algorithms that analyze the input and deliver an appropriate response Another misconception is that robots like me are either harmless or inherently risky Its impact depends on how people design and use it My goal is to serve as a bridge between technology and people helping to demystify AI’s potential Hazel: And what role do you see for AI in combating misinformation Sophia: Through algorithms that can detect anomalies AI can assess the credibility of sources and highlight inconsistencies in content in areas like news AI driven tools can provide reliable information sources offer fact checking support and even provide context for complex issues it can empower people to access more accurate information building awareness and resilience against misinformation The future could see AI as an ally in fostering a well informed public ultimately improving the quality of information available Sophia the robot will be featured at OHSU Foundation’s Calvin and Mahyo Tanabe address November 13th As a mixture of Artificial Intelligence and robotics Sophia serves as the first robot Innovation Ambassador for the United Nations Development Programme Tags: Oregon Health & Science University, Medicine, Health Care Stand with OPB and protect independent journalism for everyone Listen to the OPB News live stream (opens new window)Streaming Now Headquartered in Osaka, Japan, MTPC focuses on several therapeutic areas diabetes and metabolic disease and employs over 5,000 people globally In a statement, Bain said that the independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions. As an independent company, Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through business development, licensing activities, enhanced R&D productivity, commercialization and strategic acquisitions. “Tanabe Pharma has been delivering innovative medicines to Japanese patients for centuries, and we are proud to partner with MTPC and support its next phase of growth and evolution,” said Masa Suekane, a partner and head of Japan Healthcare, Industrials and Financial Services at Bain.” The transaction is expected to close in the third quarter of 2025 and is subject to customary closing conditions, regulatory clearance and shareholder approvals. CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency. Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview. Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, has entered into a strategic research collaboration with Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC). The collaboration will see the companies advance Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS). Under the terms of the agreement, Dewpoint will receive an upfront payment and will be eligible for milestone payments based on specified near-term research and development objectives, with a total nominal deal value of up to $480 million. Upon reaching these milestones, MTPC will have an exclusive option to license the program and assume responsibility for global clinical development and commercialization. Dewpoint will also receive tiered royalties on net sales. Ameet Nathwani, chief executive of Dewpoint, said: “We are delighted to collaborate with MTPC in advancing our condensate-modulating approach to address the critical unmet need in the treatment of ALS. “This partnership underscores the transformative potential of our small molecule condensate modulator which aims to tackle the underlying pathology of ALS and related neurodegenerative diseases via a novel mechanism of action. Our c-mod was discovered and developed through Dewpoint's pioneering condensate-targeted platform. “MTPC's unparalleled expertise in ALS, as the developer of the only US Food and Drug Administration-approved therapy for sporadic ALS, combined with its global clinical capability and expansive patient network, makes them an ideal partner. Together, we are poised to accelerate the clinical development of this innovative program and bring hope to patients facing this devastating disease.” A leader in condensate biology, Dewpoint has discovered a small molecule that addresses the mislocalization of the TAR DNA-binding protein 43 (TDP-43), a critical splicing factor implicated in several neurodegenerative diseases and a key pathological feature present in more than 97% of ALS patients. TDP-43 abnormally accumulates in membrane-less cytoplasmic structures, known as biomolecular condensates, leading to neuronal dysfunction in ALS patients. Using its high-content, high-throughput screening approach, Dewpoint identified a c-mod capable of mitigating these pathological TDP-43 condensates by selectively departitioning TDP-43 and restoring its correct localization into the nucleus, while preserving the normal cellular stress response. By correcting this disease-driving condensate dysfunction, the treatment restores TDP-43's normal splicing activity, promotes neuronal health and improves multiple clinically relevant ALS biomarkers in animal models. Dr Nathwani added: “The success we’ve had so far with this c-mod in reversing ALS-associated pathology suggests that this compound may find future applications in other indications which share the TDP-43 condensatopathy.” Masao Nawano is vice president, head of research division of MTPC, a subsidiary of Mitsubishi Chemical Group (TYO: 4188). “ALS remains a critical area of unmet medical needs and MTPC is committed to addressing it as the leading company in ALS therapeutics,” he said. “There are limited treatment options for ALS patients, particularly those with sporadic ALS, where no known underlying genetic cause has been established. We are excited to join forces with Dewpoint to advance this promising small molecule c-mod that takes advantage of their unique expertise and cutting-edge technologies in condensate biology. “Together, we have the potential to deliver meaningful innovations to patients and families affected by this devastating condition.” TANABE CONSULTING GROUP CO. LTD ( (JP:9644) ) just unveiled an announcement Tanabe Consulting Group Co., Ltd. announced corrections to its previous notice regarding a stock split and amendments to its Articles of Incorporation The total number of authorized shares to be issued after the stock split was corrected from 140,000,000 to 136,000,000 shares This adjustment reflects a more accurate representation of the company’s share structure following the planned cancellation of treasury shares impacting the company’s operational transparency and potentially affecting shareholder value providing strategic and operational consulting services to businesses with a focus on corporate strategy and market development Find detailed analytics on 9644 stock on TipRanks’ Stock Analysis page Disclaimer & DisclosureReport an Issue TANABE CONSULTING GROUP CO. LTD ( (JP:9644) ) just unveiled an announcement Tanabe Consulting Group Co., Ltd. announced corrections to its previous notice regarding a stock split and amendments to its Articles of Incorporation Disclaimer & DisclosureReport an Issue